Paper6131674
Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.
Sircar JC and 2 others. Biochem Pharmacol, 1983. Cited by 64 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Papers, record 6131674. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6131674
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminosalicylic Acids | Major topic |
| Colitis, Ulcerative | Major topic |
| Lipoxygenase Inhibitors | Major topic |
| Glycine max | Major topic |
| Sulfasalazine | Major topic |
| Humans | |
| Kinetics | |
| Mesalamine |
Source PubMed
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 18475455 | Mechanism of action of 5-arninosalicylic acid. | Mediators Inflamm | 1992 | https://conductscience.org/library/papers/18475455 | PubMed |
| 8097101 | Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen. | Br J Clin Pharmacol | 1993 | https://conductscience.org/library/papers/8097101 | PubMed |
| 6428914 | Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. | Eur J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6428914 | PubMed |
| 6201255 | The mucosal mast cell and its role in gastrointestinal allergic diseases. | Clin Rev Allergy | 1984 | https://conductscience.org/library/papers/6201255 | PubMed |
| 6150882 | Prostaglandins and ulcerative colitis. | Gut | 1984 | https://conductscience.org/library/papers/6150882 | PubMed |
| 6149981 | Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. | Gut | 1984 | https://conductscience.org/library/papers/6149981 | PubMed |
| 3458355 | Oxygen free radicals interact with indomethacin to cause gastrointestinal injury. | Agents Actions | 1986 | https://conductscience.org/library/papers/3458355 | PubMed |
| 2897215 | Sulphasalazine and PhCL28A inhibit the formation of ethanol- and phenylbutazone-induced rat gastric ulcers: lack of involvement of endogenous prostaglandins? | Br J Pharmacol | 1988 | https://conductscience.org/library/papers/2897215 | PubMed |
| 2889494 | The protective effects of sulphasalazine against ethanol-induced gastric damage in rats. | Br J Pharmacol | 1987 | https://conductscience.org/library/papers/2889494 | PubMed |
| 2882965 | Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. | Dig Dis Sci | 1987 | https://conductscience.org/library/papers/2882965 | PubMed |
| 2877850 | Pharmacological and biochemical actions of sulphasalazine. | Drugs | 1986 | https://conductscience.org/library/papers/2877850 | PubMed |
| 2869652 | Sulphasalazine and experimental stress ulcers. | Agents Actions | 1985 | https://conductscience.org/library/papers/2869652 | PubMed |
| 2866075 | Modulation of human colonic arachidonic acid metabolism by sulfasalazine. | Dig Dis Sci | 1985 | https://conductscience.org/library/papers/2866075 | PubMed |
| 2864817 | Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone. | Agents Actions | 1985 | https://conductscience.org/library/papers/2864817 | PubMed |
| 2831016 | Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. | Dig Dis Sci | 1988 | https://conductscience.org/library/papers/2831016 | PubMed |
| 2702889 | 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. | Dig Dis Sci | 1989 | https://conductscience.org/library/papers/2702889 | PubMed |
| 2664059 | Inflammatory intermediaries in inflammatory bowel disease. | Int J Colorectal Dis | 1989 | https://conductscience.org/library/papers/2664059 | PubMed |
| 2568163 | Inflammatory bowel disease. | CMAJ | 1989 | https://conductscience.org/library/papers/2568163 | PubMed |
| 2567266 | Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. | Gut | 1989 | https://conductscience.org/library/papers/2567266 | PubMed |
| 1359745 | 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. | Agents Actions | 1992 | https://conductscience.org/library/papers/1359745 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6131674
GET https://conductscience.org/api/papers/v1/6131674/authors